Variant NM_000492.4:c.254G>A
| Name | NM_000492.4:c.254G>A |
| Protein name | NP_000483.3:p.(Gly85Glu) |
| Genomic name (hg19) | chr7:g.117149177G>A UCSC |
| Genomic name (hg38) | chr7:g.117509123G>A UCSC |
| #Exon/intron | exon 3 |
| Legacy Name | G85E |
| Class | disease-causing |
| Subclass | CF-causing |
| WT sequence | TTTTTCTGGAGATTTATGTTCTATG G AATCTTTTTATATTTAGGGGTAAGG |
| Mutant sequence | TTTTTCTGGAGATTTATGTTCTATG A AATCTTTTTATATTTAGGGGTAAGG |
![]() |
![]() | dbSNP rs75961395 |
![]() | ![]() |
| Modulator | FDA approval | EMA approval | in vitro / ex vivo data | clinical data |
| IVA | no | no | no | no |
| TEZ-IVA | no | no | no | no |
| ELX-TEZ-IVA | yes | no | yes | no |
| VNZ-TEZ-DIVA | yes | no | no | yes |
clinical and functional data presented above are provided by Vertex
| Reference | PMID | Modulator | in vitro / ex vivo data | clinical data | Patient responsiveness |
| Burgel et al., 2024 | 39151434 | ELX-TEZ-IVA | N.D. | yes | yes |
1 individuals carrying this variant are reported in CFTR-NGS catalogue |
| TOTAL NUMBER OF PATIENTS | 40 |
|---|---|
| CF | 31 |
| CFTR-RD | 7
|
| Pending (NBS) | 2 |
| Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
| Phenotype | Patient ID | Variant status | Additional variants |
|---|---|---|---|
| CF | 17 | heterozygote | CF-causing - Trans |
| CF | 4967 | heterozygote | CF-causing - Trans |
| CF | 2986 | heterozygote | CF-causing - Trans |
| CF | 2985 | heterozygote | CF-causing - Trans |
| CF | 2799 | heterozygote | CF-causing- Undef |
| CF | 2475 | heterozygote | CF-causing- Undef |
| CF | 2220 | heterozygote | CF-causing- Undef |
| CF | 2154 | heterozygote | CF-causing- Undef |
| CF | 3649 | heterozygote | CF-causing- Undef |
| CF | 4379 | heterozygote | CF-causing - Trans |
| CF | 4341 | heterozygote | CF-causing - Trans VUS3 - Trans |
| CF | 4340 | heterozygote | varying clinical consequence - Trans |
| CF | 4339 | heterozygote | varying clinical consequence - Trans |
| CF | 4332 | heterozygote | varying clinical consequence - Trans |
| CF | 3960 | heterozygote | CF-causing- Undef |
| CF | 3826 | heterozygote | CF-causing- Undef |
| CF | 1959 | heterozygote | CF-causing- Undef |
| CF | 1927 | heterozygote | CF-causing- Undef |
| CF | 267 | heterozygote | CF-causing- Undef |
| CF | 307 | heterozygote | CF-causing - Trans |
| CF | 310 | heterozygote | CF-causing - Trans |
| CF | 5515 | heterozygote | VUS3 - Trans |
| CF | 5516 | heterozygote | VUS3 - Trans |
| CF | 1036 | heterozygote | CF-causing - Trans |
| CF | 1172 | heterozygote | CF-causing - Trans |
| CF | 5389 | heterozygote | CF-causing- Undef |
| CF | 1779 | heterozygote | CF-causing- Undef |
| CF | 6516 | heterozygote | varying clinical consequence- Undef |
| CF | 4867 | heterozygote | CFTR-RD-causing- Undef |
| CF | 1206 | heterozygote | CF-causing - Trans |
| CF | 172 | homozygote | c.254G>A - p.(Gly85Glu) - Trans |
| Pending (NBS) | 4693 | heterozygote | CFTR-RD-causing - Trans |
| Pending (NBS) | 6011 | heterozygote | varying clinical consequence- Undef |
| CRS-NP | 4384 | heterozygote | varying clinical consequence - Trans |
| CRS-NP | 295 | heterozygote | CFTR-RD-causing - Trans |
| Pancreatitis | 648 | heterozygote | CFTR-RD-causing - Trans |
| CBAVD | 2425 | heterozygote | CFTR-RD-causing- Undef |
| CBAVD | 3734 | heterozygote | CF-causing- Undef |
| CBAVD | 1759 | heterozygote | CFTR-RD-causing- Undef |
| Bronchiectasis | 5112 | heterozygote | varying clinical consequence- Undef |
| Color code: non disease-causing < likely benign < VUS < likely pathogenic < disease-causing |
| CFTR variants are clustered into five groups (click here for more details about the classification of variants): |
|